Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 125

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 125
---
 2025, and we further expect to submit
our PMA by the end of 2027.

Research and Development

Having grown out of research
from The Technion Israel Institute of Technology, our commitment to research and innovation is best witnessed by the development we carried
out on GelrinC to-date from the underlying science and our close relationship with our founder Professor Dror Seliktar of The Technion.
We believe we have the expertise onboard to continue to build our product lines, including advancing future products and additional applications
(such as GelrinP).

Intellectual Property

Our success will depend in
part on obtaining and maintaining patents, trade secrets and other intellectual property and protection of our technology, current and
future product candidates and methods used to develop and manufacture them. We cannot be sure that any of our currently pending patent
applications or with respect to any patent applications that we file in the future will be granted, nor can we be sure that our existing
patents or any patents that may be granted to us in the future will be sufficient to protect our technology or will not be challenged,
invalidated or circumvented. Our success also depends on our ability to operate our business without infringing, misappropriating or otherwise
violating any patents and other intellectual property or proprietary rights of third parties.

The scope of patent protection
for the major products that are already approved for marketing and/or in development by the Company include granted or issued patents.
The main composition of matter patents claim protein-polymer conjugates of an extracellular matrix protein (e.g. fibrinogen) or a serum
protein, (e.g., albumin) covalently bound to a synthetic polymer (e.g. polyethylene glycol, polaxamer), as well as uses of these compositions
for treating cartilage injuries or osteoarthritis and scaffolds formed from these conjugates. Additionally, there is a family of patents
claiming a unique device for effective administration of the compositions to the patient and supplies a source of UVA irradiation that
initiates the crosslinking to form the scaffolds.

The scope of the claims of
the granted/issued patents covers both GelrinC and GelrinP, including their uses and processes for making them, as well as supplementary
protection for a specific device for administration of the compositions. In addition, there are additional pending families of applications
that may provide supplementary levels of protection for improvements in the products and the processes of manufacture.

Specifically, while the